Rose is a managing editor at The American Journal of Managed Care® (AJMC®).
She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on LinkedIn.
Dr Kevan Herold Explains Teplizumab's Potential in Newly Diagnosed T1D
Kevan Herold, MD, professor of immunobiology and medicine at Yale School of Medicine, discussed recently published results from the PROTECT trial of teplizumab in patients newly diagnosed with type 1 diabetes (T1D).
FDA Approves Belzutifan for Advanced RCC After PD-1 or PD-L1 Inhibition and a VEGF-TKI
The approval of belzutifan, an oral hypoxia-inducible factor-2 alpha inhibitor, provides a new option for patients with advanced renal cell carcinoma (RCC) following treatment with a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).
Dr Ibrahim Aldoss on the Need for Targeted Therapy for KMT2Ar Acute Leukemias
Ibrahim T. Aldoss, MD, of City of Hope Comprehensive Cancer Center, discusses the potential of revumenib in KMT2A-rearranged (KMT2Ar) acute leukemias, with pivotal results presented at the 65th Annual American Society of Hematology Annual Meeting and Exposition this week.
Frontline Daratumumab Plus VRd Outperforms Standard VRd Alone in Multiple Myeloma
A late-breaking abstract presented at the American Society of Hematology Annual Meeting and Exposition supports the addition of subcutaneous daratumumab to standard-of-care bortezomib, lenalidomide, and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation.
ICYMI: Highlights From the 2023 Community Oncology Conference
Our top coverage from this year’s Community Oncology Conference, hosted by the Community Oncology Alliance, included discussions around alternative payment models, shifts in the community oncology landscape in recent decades, and the need for reform in several areas.
Dr David Andorsky on BTK Inhibitor Treatment Patterns and SDOH in CLL, SLL
David J. Andorsky, MD, board-certified medical oncologist and hematologist at Rocky Mountain Cancer Centers, discussed findings from a study on patterns of Bruton tyrosine kinase (BTK) inhibitor care use and social determinants of health (SDOH) among patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Is Genome Editing the Next Step in Immunotherapy Innovation? Experts Think So
Presenters at the American Society of Hematology Annual Meeting and Exposition agreed that novel strategies, such as CRISPR and base editing, have potential to fine-tune the latest immunotherapy advancements to increase the efficacy and durability of a range of treatments.
Dr Andrew Srisuwananukorn on the Potential for AI in Differentiating prePMF and ET
Andrew Srisuwananukorn, MD, of the Ohio State University Comprehensive Cancer Center, explained the potential of artificial intelligence (AI)-based support tools for differentiating primary myelofibrosis (prePMF) and essential thrombocythemia (ET) in the community setting.
Cellular Therapies in Lymphoma Bring Hope, but Optimizing Their Use Remains a Challenge
Recent decades have seen marked improvements in hematological cancer outcomes and an expanded armamentarium of therapies, but novel treatments require updated strategies that are not always easy to fine-tune, according to presenters at the 2023 American Society of Hematology Annual Meeting and Exposition.
Dr Jennifer Brown: Zanubrutinib Efficacy Holds Up at ALPINE 39-Month Follow-Up in R/R CLL
Jennifer R. Brown, MD, PhD, director of the Chronic Lymphocytic Leukemia (CLL) Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute, discussed the updated findings from the phase 3 ALPINE trial of zanubrutinib vs ibrutinib in relapsed/refractory CLL (R/R CLL) at 39 months of follow-up.
Dr Mrinal Gounder: Nirogacestat Approval Provides First-in-Class Option for Desmoid Tumor Treatment
Mrinal M. Gounder, MD, a sarcoma oncologist at Memorial Sloan Kettering Cancer Center and lead investigator of the phase 3 DeFi trial of nirogacestat in desmoid tumors, discusses the drug's recent FDA approval and potential impacts on desmoid tumor treatment going forward.
Dr Mikkael Sekeres: ASH 2023 to Foster Discussion of Timely Themes, the Latest Data in Hematology
Mikkael A. Sekeres, MD, chief of the Division of Hematology at Sylvester Comprehensive Cancer Center, University of Miami, and chair of the American Society of Hematology (ASH) Committee on Communications, discusses the themes of the upcoming ASH Annual Meeting & Exposition 2023.
Dr Jennifer Brown Previews CLL Research Being Presented at ASH 2023
Jennifer R. Brown, MD, PhD, director of the Chronic Lymphocytic Leukemia (CLL) Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute, previewed her presentation of extended follow-up data from the phase 3 ALPINE trial and other studies of interest to CLL specialists at the 2023 American Society of Hematology (ASH) Annual Meeting.
Dr Guru Sonpavde on the Potential of Nivolumab Plus Chemotherapy in Urothelial Carcinoma
Guru Sonpavde, MD, medical director of genitourinary oncology at the AdventHealth Cancer Institute, discussed the promising findings of the CheckMate 901 trial exploring the potential of nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma.
Study Finds ASCT Similarly Safe, Effective in Older and Younger Patients With Multiple Myeloma
A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.
Dr Guru Sonpavde: Nivolumab Plus Gemcitabine-Cisplatin Holds Promise in Urothelial Cancer
Urothelial carcinoma has long been treated with chemotherapy as the frontline standard of care, but recent trial results in the space have potential to add to the treatment armamentarium and improve outcomes for the first time in decades.
Study Shows Higher Infection Risk in Patients With T1D in Primary, Secondary Care
Researchers concluded there is a clinically important increase in infection risk among patients with T1D in both primary care and hospital settings, and that guidelines must be developed to reflect this risk and encourage earlier treatment.
CDC Report Shows Decline in Youth Cancer Mortality, Highlights Racial and Ethnic Disparities
While the overall rate of cancer death among children has declined substantially in recent decades, progress has stalled for Black and Hispanic children compared with White children since 2011.
Review Explores Link Between Tumor Burden, CAR T-Cell Therapy Efficacy
A recent review aimed to characterize the relationship between tumor burden and clinical outcomes in patients treated with chimeric antigen receptor (CAR) T-cell therapy, highlighting the potential mechanisms of high tumor burden impacting CAR T-cell failure.
Remibrutinib Shows Promise for Chronic Spontaneous Urticaria in Phase 3 Trials
Remibrutinib, an investigational, highly selective Bruton tyrosine kinase inhibitor, showed favorable results in the treatment of chronic spontaneous urticaria (CSU) in as early as 2 weeks in the phase 3 REMIX-1 and REMIX-2 studies.
Recent T1D Research Contradicts Common Assumptions About Patients
Michael Fang, PhD, researcher and assistant professor in the division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University, discussed recent findings in the type 1 diabetes (T1D) space that may alter the way providers address diabetes diagnoses.